Related Experiment Video

Updated: Jul 1, 2026

Focused Assessment with Sonography for Trauma FAST Exam: Image Acquisition
07:18

Focused Assessment with Sonography for Trauma FAST Exam: Image Acquisition

Published on: September 22, 2023

7.7K

Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System

Christopher R Frei1,2,3, Hannah Le4, Daniel McHugh4

  • 1South Texas Veterans Health Care System, San Antonio, TX, USA.

Leukemia & Lymphoma
|February 11, 2021
PubMed

Insights

Adverse events (AEs) frequently led to treatment discontinuation for novel oral agents in US veterans with chronic lymphocytic leukemia (CLL). Physician inexperience may have contributed to these outcomes.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • US veterans exhibit elevated chronic lymphocytic leukemia (CLL) risk factors.
  • Novel oral agents represent a significant advancement in CLL treatment.

Purpose of the Study:

  • To evaluate the real-world effectiveness and tolerability of novel oral agents in a US veteran population with CLL.
  • To identify reasons for treatment discontinuation, particularly adverse events (AEs).

Main Methods:

  • Retrospective chart review of 1205 CLL patients from the Veterans Health Administration (VHA) initiating novel oral agent therapy.
  • Analysis of discontinuation rates and reasons, focusing on AEs for ibrutinib, venetoclax, and idelalisib.

Main Results:

  • Discontinuation rates varied: 33% for first-line ibrutinib, 35% for relapsed/refractory (R/R) ibrutinib, 31% for R/R venetoclax, and 84% for idelalisib.
  • AEs were a primary reason for discontinuation across all agents, ranging from 41% for venetoclax to 64% for first-line ibrutinib.
  • Physician inexperience with these agents during their early introduction may have influenced outcomes.

Conclusions:

  • Adverse events significantly impact treatment adherence and outcomes in CLL patients treated with novel oral agents.
  • Real-world data highlights the importance of managing AEs and suggests a learning curve for physicians using these therapies.

Keywords:
Chronic lymphocytic leukemiaadverse eventschart reviewdiscontinuationdose reductionnovel agents

More Related Videos

Diaphragmatic Ultrasound in Adults: Image Acquisition and Interpretation05:51

Diaphragmatic Ultrasound in Adults: Image Acquisition and Interpretation

Published on: January 31, 2025

1.1K
Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting03:40

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting

Published on: January 17, 2025

577

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...